Behzad Hajarizadeh

List of Publications by Year
in descending order

145 papers	8,797 citations	71061 41 h-index	45285 90 g-index
146 all docs	146 docs citations	146 times ranked	9133 citing authors

#	Article	IF	Citations
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	3.7	1,619
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	3.7	1,241
3	Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 553-562.	8.2	833
4	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of Hepatology, 2017, 67, 1204-1212.	1.8	390
5	The effects of female sex, viral genotype, andIL28Bgenotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology, 2014, 59, 109-120.	3.6	320
6	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237
7	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 153-161.	3.7	231
8	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 754-767.	3.7	174
9	Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. International Journal of Drug Policy, 2017, 47, 34-46.	1.6	158
10	Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 641-651.	8.2	127
11	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. The Lancet Gastroenterology and Hepatology, 2017, 2, 514-520.	3.7	123
12	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 4-20.	1.0	109
13	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.	1.8	103
14	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. Journal of Infectious Diseases, 2018, 217, 1889-1896.	1.9	88
15	Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfectionâ€”the InC³Study. Journal of Infectious Diseases, 2015, 212, 1407-1419.	1.9	82
16	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 317-327.	3.7	80
17	Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Archives of Iranian Medicine, 2006, 9, 319-23.	0.2	77
18	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Journal of Hepatology, 2019, 71, 281-288.	1.8	76

#	Article	IF	Citations
19	Nonâ€alcoholic fatty liver disease prevalence among schoolâ€aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver International, 2009, 29, 159-163.	1.9	70
20	Uptake of directâ€acting antiviral treatment for chronic hepatitis C in Australia. Journal of Viral Hepatitis, 2018, 25, 640-648.	1.0	68
21	Elimination of Hepatitis C Virus in Australia. Infectious Disease Clinics of North America, 2018, 32, 269-279.	1.9	65
22	Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepatitis Monthly, 2016, 16, e40959.	0.1	63
23	Strategies to manage hepatitis C virus infection disease burden â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 42-65.	1.0	62
24	Management of acute HCV infection in the era of direct-acting antiviral therapy. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 412-424.	8.2	62
25	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 21-41.	1.0	61
26	Chronic hepatitis C burden and care cascade in Australia in the era of interferonâ€based treatment. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 229-236.	1.4	61
27	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005â€2014: The <scp>HITS</scp>â€p study. Journal of Viral Hepatitis, 2017, 24, 733-741.	1.0	61
28	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. Journal of Hepatology, 2018, 68, 393-401.	1.8	58
29	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International Journal of Drug Policy, 2018, 62, 14-23.	1.6	58
30	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. Journal of Viral Hepatitis, 2019, 26, 83-92.	1.0	58
31	Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia. BMC Research Notes, 2011, 4, 45.	0.6	57
32	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. International Journal of Drug Policy, 2018, 61, 23-30.	1.6	57
33	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical Infectious Diseases, 2020, 71, e115-e124.	2.9	53
34	Higher incidence of <scp>HCV</scp> in females compared to males who inject drugs: A systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2017, 24, 117-127.	1.0	51
35	Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2022, 7, 426-445.	3.7	50
36	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2021, 6, 533-546.	3.7	48

#	Article	IF	Citations
37	Case definitions for acute hepatitis C virus infection: A systematic review. Journal of Hepatology, 2012, 57, 1349-1360.	1.8	46
38	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Current HIV/AIDS Reports, 2017, 14, 110-121.	1.1	46
39	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. International Journal of Drug Policy, 2018, 54, 18-25.	1.6	46
40	Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology, 2003, 8, 256-260.	0.7	44
41	Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepatitis Monthly, 2016, 16, e37234.	0.1	44
42	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A metaâ€analysis. Hepatology, 2022, 76, 139-154.	3.6	42
43	Hepatitis B knowledge and associated factors among people with chronic hepatitis B. Australian and New Zealand Journal of Public Health, 2015, 39, 563-568.	0.8	41
44	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	1.1	41
45	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. International Journal of Drug Policy, 2019, 72, 1-10.	1.6	40
46	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs preâ€and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	1.0	39
47	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e107-e118.	2.9	39
48	More than a virus: a qualitative study of the social implications of hepatitis B infection in China. International Journal for Equity in Health, 2017, 16, 137.	1.5	38
49	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000â€“2014). Journal of Hepatology, 2016, 65, 1086-1093.	1.8	36
50	Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 836-840.	1.4	35
51	Sexual Function: A Comparison Between Male Renal Transplant Recipients and Hemodialysis Patients. Journal of Sexual Medicine, 2009, 6, 142-148.	0.3	33
52	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology, 2017, 92, 32-38.	1.6	32
53	Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour". Sexually Transmitted Infections, 2005, 81, 185-185.	0.8	31
54	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. Journal of Hepatology, 2016, 65, 879-887.	1.8	29

#	Article	IF	Citations
55	Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Science Translational Medicine, 2018, 10, .	5.8	29
56	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 230-238.	1.6	28
57	Trends and geographical inequalities of the main health indicators for rural Iran. Health Policy and Planning, 2009, 24, 229-237.	1.0	27
58	An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. International Journal of Drug Policy, 2019, 72, 99-105.	1.6	27
59	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. Journal of Hepatology, 2021, 74, 293-302.	1.8	27
60	Dynamics of HCV RNA levels during acute hepatitis C virus infection. Journal of Medical Virology, 2014, 86, 1722-1729.	2.5	26
61	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases, 2021, 72, 1392-1400.	2.9	26
62	Global cascade of care for chronic hepatitis C virus infection: A systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2021, 28, 1340-1354.	1.0	26
63	Hepatitis C virus testing, liver disease assessment and directâ€acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 2019, 26, 969-979.	1.0	25
64	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. Journal of Infectious Diseases, 2022, 226, 1005-1021.	1.9	24
65	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. Lancet HIV,the, 2022, 9, e414-e427.	2.1	23
66	Challenges in managing patients in Australia with chronic hepatitis B: the General Practitionersâ€™ perspective. Australian and New Zealand Journal of Public Health, 2013, 37, 405-410.	0.8	22
67	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International Journal of Drug Policy, 2018, 62, 94-103.	1.6	22
68	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infectious Diseases, 2018, 18, 215.	1.3	22
69	Systematic review with metaâ€analysis: effectiveness of directâ€acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2020, 51, 34-52.	1.9	22
70	Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades. Journal of Public Health, 2008, 30, 499-504.	1.0	21
71	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. Clinical Infectious Diseases, 2018, 66, 20-28.	2.9	21
72	Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia. Sexual Health, 2012, 9, 131.	0.4	19

#	Article	IF	Citations
73	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. Journal of Viral Hepatitis, 2018, 25, 473-481.	1.0	19
74	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clinical Infectious Diseases, 2020, 70, 2369-2376.	2.9	19
75	Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocrine Disorders, 2004, 4, 4.	0.9	18
76	Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. International Journal of Drug Policy, 2019, 73, 129-134.	1.6	18
77	Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology, 2008, 13, 376-379.	0.7	17
78	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. Journal of Molecular Diagnostics, 2018, 20, 621-627.	1.2	17
79	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. Journal of Infectious Diseases, 2020, 221, 2043-2049.	1.9	16
80	Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. International Journal of Drug Policy, 2021, 96, 103422.	1.6	15
81	Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia. Hepatitis Monthly, 2016, 16, e35566.	0.1	14
82	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³ study. Journal of Viral Hepatitis, 2015, 22, 708-717.	1.0	13
83	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infection, Genetics and Evolution, 2016, 37, 252-258.	1.0	13
84	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 177-186.	1.6	13
85	Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. PLoS ONE, 2021, 16, e0257369.	1.1	13
86	Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. Journal of Viral Hepatitis, 2019, 26, 1423-1430.	1.0	12
87	Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 6168-6176.	0.7	12
88	Estimating the Prevalence of Hepatitis B Virus Infection and Exposure Among General Population in Iran. Hepatitis Monthly, 2017, 17, .	0.1	12
89	Generic Direct Acting Antiviral Treatment: The First Step Towards Elimination of Hepatitis C in Iran. Hepatitis Monthly, 2017, 17, .	0.1	12
90	Letter: the rs12979860 and ss469415590 polymorphisms ofIFNL4gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2014, 39, 343-343.	1.9	11

#	Article	IF	Citations
91	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clinical Infectious Diseases, 2022, 75, 1809-1819.	2.9	11
92	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. Virology Journal, 2016, 13, 32.	1.4	10
93	Editorial: Observations on the launch of new drugs for hepatitis C. Australian Prescriber, 2018, 41, 4-5.	0.5	10
94	High Effectiveness of Broad Access Directâ€Acting Antiviral Therapy for Hepatitis C in an Australian Realâ€World Cohort: The REACHâ€C Study. Hepatology Communications, 2022, 6, 496-512.	2.0	10
95	Is preemptive renal transplantation preferred?. Transplantation Proceedings, 2003, 35, 2598-2601.	0.3	9
96	Hepatitis C elimination in Australia: progress and challenges. Medical Journal of Australia, 2020, 212, 362-363.	0.8	9
97	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and metaâ€analysis. Addiction, 2021, 116, 1664-1676.	1.7	9
98	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToPâ€C Treatment as Prevention Study in Prisons. Hepatology, 2021, 74, 2366-2379.	3.6	9
99	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	1.6	8
100	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 2016, 36, 1774-1782.	1.9	8
101	No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. Journal of Hepatology, 2017, 66, S12.	1.8	8
102	The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. Journal of Hepatology, 2017, 66, S291-S292.	1.8	8
103	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000â€2014). Hepatology Communications, 2017, 1, 736-747.	2.0	8
104	Addressing cultural diversity: the hepatitis B clinical specialist perspective. Ethnicity and Health, 2019, 24, 816-828.	1.5	8
105	Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. Journal of Viral Hepatitis, 2021, 28, 710-718.	1.0	8
106	Prescribing of directâ€acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. Medical Journal of Australia, 2021, 215, 332-333.	0.8	8
107	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. Sexual Health, 2020, 17, 223.	0.4	8
108	Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia. Viruses, 2022, 14, 1496.	1.5	8

#	Article	IF	Citations
109	Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples. Journal of Infectious Diseases, 2021, 223, 818-826.	1.9	7
110	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	1.6	7
111	Managing chronic hepatitis B - the role of the GP. Australian Family Physician, 2012, 41, 893-8.	0.5	7
112	Retreatment for hepatitis C virus directâ€acting antiviral therapy virological failure in primary and tertiary settings: The <scp>REACHâ€C</scp> cohort. Journal of Viral Hepatitis, 2022, 29, 661-676.	1.0	7
113	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses, 2022, 14, 1555.	1.5	7
114	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infectious Diseases, 2017, 17, 420.	1.3	6
115	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. Journal of Medical Virology, 2018, 90, 120-130.	2.5	6
116	Disease progression during advanced fibrosis:IL28Bgenotype or HCV RNA levels?. Hepatology, 2014, 59, 1650-1651.	3.6	5
117	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. BMC Infectious Diseases, 2016, 16, 241.	1.3	5
118	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. Journal of Hepatology, 2019, 70, e733.	1.8	5
119	Allâ€cause hepatocellular carcinoma survival in the era of directâ€acting antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	5
120	Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients. Transplantation Proceedings, 2003, 35, 2687-2688.	0.3	4
121	Patient and graft outcome after living donor renal transplantation in Iran: more than 15-year follow-up. Transplantation Proceedings, 2003, 35, 2605-2606.	0.3	4
122	Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?. Liver International, 2014, 34, 964-964.	1.9	4
123	Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake. Journal of Hepatology, 2018, 68, S153.	1.8	4
124	Interferon Î» 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. Journal of Molecular Diagnostics, 2015, 17, 583-589.	1.2	3
125	Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study. Journal of Hepatology, 2017, 66, S274.	1.8	3
126	O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued. Journal of Virus Eradication, 2017, 3, 5.	0.3	3

#	Article	IF	Citations
127	1157 EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION. Journal of Hepatology, 2013, 58, S470-S471.	1.8	2
128	Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study. Journal of Hepatology, 2017, 66, S513.	1.8	2
129	Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study. Journal of Hepatology, 2018, 68, S187-S188.	1.8	2
130	Cure and Control: What Will It Take to Eliminate HCV?. Topics in Medicinal Chemistry, 2019, , 447-490.	0.4	2
131	Patients' perspectives on the delivery of hepatitis B management and care. Australian Family Physician, 2015, 44, 346.	0.5	2
132	461 SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION. Journal of Hepatology, 2013, 58, S189.	1.8	1
133	Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools. Journal of Hepatology, 2017, 66, S710.	1.8	1
134	Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia. BMC Public Health, 2022, 22, 536.	1.2	1
135	Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open, 2022, 12, e058757.	0.8	1
136	PIN15 COMPARING COST-EFFECTIVENESS OF THE THREE- VERSUS TWO-DOSE VACCINATION PROTOCOL AGAINST HEPATITIS B IN ADOLESCENTS. Value in Health, 2009, 12, A112.	0.1	0
137	PIN27 COST ANALYSIS OF THE MASS VACCINATION CAMPAIGN AGAINST HEPATITIS B IN ADOLESCENTS IN IRAN. Value in Health, 2009, 12, A114.	0.1	0
138	P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study. Journal of Hepatology, 2015, 62, S657.	1.8	0
139	Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting, 2005â€“2014: The Hits-P Study. Journal of Hepatology, 2016, 64, S614.	1.8	0
140	Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse. Journal of Hepatology, 2016, 64, S625-S626.	1.8	0
141	Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005â€“2014: the HITS-p study. Journal of Hepatology, 2017, 66, S488.	1.8	0
142	A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit. Journal of Hepatology, 2017, 66, S495.	1.8	0
143	Field evaluation of Xpert Â® HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples. Journal of Hepatology, 2017, 66, S709.	1.8	0
144	Evaluation of the Xpert fingerstick HCV viral load assay. Journal of Hepatology, 2018, 68, S167.	1.8	0

#	Article	IF	Citations
145	HCV Elimination in Australia. , 2021, , 213-227.		0